ARRAY MARKET (LIFE SCIENCE AND BIOTECHNOLOGY INSTRUMENTS) ANALYSIS

The global array market (Life Science and Biotechnology Instruments) is estimated to be valued at US$ 7.4 Billion in 2023 and is expected to exhibit a CAGR of 15.4% during the forecast period (2023-2030).

Analysts’ Views on Global Array Market (Life Science and Biotechnology Instruments):

A rising number of growth strategies, such as partnerships and others, by the key market players for cell and gene therapy are expected to propel market growth over the forecast period. For instance, on July 18, 2023, Arrayjet, a leading provider of inkjet liquid-handling solutions, announced that it had entered into a partnership with Chemspace, an online catalogue of small molecules and biologics, to augment and streamline the company’s small molecule microarray (SMM) service offering. Chemspace’s curated and deeply annotated compound libraries are now accessible through Arrayjet’s SMM Contract Research Organizations and Contract Manufacturing Organizations services for assay development, contract screening, and contract array manufacturing.

Figure 1. Global Array Market (Life Science and Biotechnology Instruments) Share (%), By Type, 2023 

To learn more about this report, request sample copy

Global Array Market (Life Science and Biotechnology Instruments) – Driver

Rising strategic initiatives taken by the market players

The key market players are focused on strategic initiatives, which in turn is expected to fuel market growth over the forecast period. For instance, in March 2021, Oxford BioDynamics Plc, a global biotechnology company, and Agilent Technologies, a provider of scientific solutions, announced that they had signed a supply and resale agreement for the manufacturing and sale of new EpiSwitch Explorer Array Kit. EpiSwitch Explorer Array Kit is a microarray kit available for high-resolution 3D (3- Dimensional) genome profiling and biomarker discovery.

Increasing prevalence of cancer

Increasing changes in lifestyles is considered a major cause of cancer. Thus, the increasing prevalence of cancer globally is expected to boost growth of the market over the forecast period, as arrays are used in diagnostics for various indications such as cancer and others. For instance, according to the data published by the American Cancer Society 2021, cancer facts and figures, in the U.S., reported the estimated cancer cases in the U.S. in 2021, which is provided below:

Figure 2. Global Array Market (Life Science and Biotechnology Instruments) Share (%), By Region, 2023

To learn more about this report, request sample copy

Global Array Market (Life Science and Biotechnology Instruments) - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global array market (Life Science and Biotechnology Instruments) over the forecast period. This is attributed to the increasing number of clinical trials conducted by market players. For instance, on June 5, 2023, Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, announced positive interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.

Global Array Market (Life Science and Biotechnology Instruments) – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

The COVID-19 pandemic had a positive impact on the global array market (Life Science and Biotechnology Instruments), owing to increased research and development activities using array in the treatment of patients suffering from COVID-19. For instance, in August 2020, according to the report published by Aurora Biomed Inc., a provider of lab automation solutions for life science, environmental science, drug discovery and safety and chemical analysis research, microarray, including cell microarray, protein microarrays, and DNA and RNA microarray, are all considered powerful tools in the ongoing research related to COVID-19. These microarrays can analyze hundreds or even thousands of samples in a single run, making them much faster than traditional virus detection methods. These techniques allow researchers to rapidly screen for the presence of viral proteins in samples, providing valuable information about the virus and its behavior.

Furthermore, in January 2022, according to the published article titled "Systematic Investigation of SARS-CoV-2 Receptor Protein Distribution along Viral Entry Routes in Humans", tissue microarrays incorporating a total of 879 tissue cores from conjunctival (n = 84), sinonasal (n = 95), and lung (bronchiolar/alveolar; n = 96) specimens were investigated for protein expression by immunohistochemistry. The study confirms and extends previous findings and contributes to a better understanding of potential SARS-CoV-2 infection sites along the human respiratory tract. Such studies indicate significant demand for tissue microarray products amid the pandemic.

Global Array Market (Life Science and Biotechnology Instruments) Segmentation:

The global array market (life science and biotechnology instruments) report is segmented into type, end user, and region

Based on Type, the global array market (life science and biotechnology instruments) is segmented into DNA array, protein array, tissue array, cell array, and others (peptide array andoOthers). Out of which, the DNA array segment is expected to dominate the global array market (life science and biotechnology instruments) during the forecast period, and this is due to increasing research and development activities by the market players.

Based on End user, the global array market (life science and biotechnology instruments) is segmented into biopharmaceutical and pharmaceutical companies, diagnostic laboratories, research laboratories, and others (Academic Institutes, and Others). The diagnostic laboratories segment is expected to dominate the market over the forecast period, and this is due to the increasing demand for diagnostic laboratories for the diagnosis of various diseases such as cancer and others.

Based on Region, the global array market (Life Science and Biotechnology Instruments) is segmented into North America, Latin America. Europe, Asia Pacific, Middle East and Africa. Out of which, the North America region is expected to dominate the market over the forecast period, and this is due to the increasing prevalence of cancer cases in this region.

Among all the segmentations, the type segment has the highest potential due to the increasing inorganic growth strategies, such as acquisitions and others, by the key market players. For instance, in September 2021, SCHOTT MINIFAB, a subsidiary of SCHOTT, a technology company that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, announced that they had acquired Applied Microarrays Inc. (AMI), a U.S.-based company, which will further help the company in strengthening of single-source contract manufacturing solution in the North America Region.

Global Array Market (Life Science and Biotechnology Instruments) Cross Sectional Analysis:

Increasing collaboration between the key market players for the expansion of their products in the market is expected to fuel the type segment growth in the North America region. For instance, in November 2020, PEPperPRINT, a biotechnology company, announced a collaboration with Lucerna-Chem, a laboratory equipment supplier, so that customers could now access PEPperCHIP Peptide Microarray products and PEPperMAP Services via Lucerna-Chem owing to a new distribution arrangement. As a result, such agreements are projected to boost market growth in the region by offering advanced instruments.

Global Array Market (Life Science and Biotechnology Instruments): Key Developments

In November 2022, Sengenics, a precision medicine company, announced the commercial launch of Dual-Color IgG/IgA Assay Services. The new Dual-Color Assays accelerate the pace and expand the biological space in the quest to discover new autoantibody biomarkers.

In October 2020, researchers emphasized in an article published in the Journal of Proteins & Proteomics that advances in proteome technology will not only expedite efforts in combating the coronavirus pandemic but will also help to address the current COVID-19 situation.

In February 2020, the U.S. Food & Drug Administration changed the definition of a biologic to include in synthetic peptides and chemically synthesized polypeptides with a sequence of at least 40 amino acids but no more than 100 amino acids (synthetic proteins).

In April 2021, the National Center for Biotechnology information announced the introduction of CovidArray, a microarray-based test to detect COVID-19 markers N1 and N2 in nasopharyngeal swab samples. The universal microarray can detect the genotypes of six mutated bases related to COVID-19.

Global Array Market (Life Science and Biotechnology Instruments): Key Trends

Increasing fundings by the market players

Increasing growth strategies by the market players, such as funding and others, are expected to drive growth of the market over the forecast period. For instance, in June 2022, Ariceum Therapeutics, a private clinical-stage radiopharmaceutical company, announced funding of US$ 25 million in Series A to enhance its lead asset, Satoreotide, for the diagnosis of low- and high-neuroendocrine cancers.

Increasing prevalence of various chronic disease

Increasing prevalence of various chronic diseases, such as cancer, multiple myloma, and others, is expected to foster market growth over the forecast period. For instance, According to the estimates by the GLOBOCAN 2020, around 6,900 new cases of multiple myeloma were diagnosed in Southeast Asia.

Furthermore, according to the estimates by GLOBOCAN 2020, around 2,155 new cancer cases were diagnosed in the UAE.

Global Array Market (Life Science and Biotechnology Instruments): Restraints

Lack of technically trained resources

Lack of technically trained resources, especially in emerging economies, is expected to hinder growth of the global array market (life science and biotechnology instruments). Technologically versed and skilled resources are a prerequisite for using DNA and gene microarrays and sequencers. A shortage of such trained personnel is expected to limit market growth.

To overcome these kind of challenges manufacturers operating in this market should appoint well qualified person having technical knowledge about different types of arrays

High cost of Microarray Sequencing

The high cost of microarray sequencing used in various applications, such as cancer and others, is expected to hinder market growth over the forecast period. For instance, in June 2022, according to the report published in the National Center for Biotechnology Information, the reported price of microarrays used in cancer diagnostic ranged from US$ 335 to US$ 700.

To overcome this high cost government has given reimbursement policies which the patient’s must opt for to avail proper discount and avoid out of pocket expenses

Global Array Market (Life Science and Biotechnology Instruments) - Key Players

• Major players operating in the global array market (Life Science and Biotechnology Instruments) include Thermo Fisher Scientific Inc., Illumina, Inc., Roche Diagnostics Nederland B.V., Bio-Rad Laboratories, Inc., Life Technologies, Caliper Life Sciences, Perkin Elmer, Inc., Siemens Healthineers, Agilent Technologies Inc., PathogenDx, Inc., Twist Bioscience Corporation, Arraylt Corporation, Molecular Device, LLC and Raybiotech Inc.

*Definition: A DNA microarray or chip is a semiconductor surface on which sequences of many varied genes are bonded to probes. DNA microarrays are used to quantify the expression levels of large numbers of genes simultaneously or to genotype multiple regions of a genome. The approach finds application in drug R&D, clinical diagnosis, agriculture, environmental control, and other sectors.